Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Hartz, Susanne ^a   Getsios, Denis ^b   Tao, Sunning ^c   Blume, Steve ^b   Maclaine, Grant ^d  

^a B214 Baquba Building ^*  (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c UNITED BIOSOURCE CORPORATION   (Canada)

^d Becton Dickinson UK Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAREGIVER; CAREGIVER SUPPORT; COGNITION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE SYSTEM; HUMAN; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; GERMANY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DOPAMINE AGENTS; GERMANY; HUMANS; INDANS; MEMANTINE; PIPERIDINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 84856623571     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-2     Document Type: Article

References (56)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004, 351(1):56-67. 10.1056/NEJMra040223, 15229308.
2. Ziegler U. DG: prevalence and incidence of dementia in Germany -- a study based on data from the public sickness funds in 2002. Gesundheitswenen 2009, 71:281-290.
3. BMG. , http://www.bmg.bund.de/cln_110/nn_1168278/SharedDocs/Standardartikel/DE/AZ/D/Glossarbegriff-Demenz.html
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, (1):CD005593.
5. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008, 3(2):211-225. 2546466,2546466, 18686744.
6. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007, 14(1):e1-e26.
7. Melchinger H. Demenzerkrankungen. Chronische Versorgungsdefizite. Dtsch Arztebl 2007, 104(47):A3236-A3237.
8. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 2007, 25(9):735-750. 10.2165/00019053-200725090-00003, 17803333.
9. Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: state of the art and future directions. Alzheimers Dement 2008, 4(3):212-222. 10.1016/j.jalz.2008.02.003, 18631970.
10. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 2002, 13(1):33-39. 10.1159/000048631, 11731713.
11. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML, Forette F. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 2004, 17(1-2):5-13. 10.1159/000074079, 14560059.
12. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2005, 23(12):1271-1282. 10.2165/00019053-200523120-00010, 16336020.
13. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999, 47(5):570-578.
14. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999, 21(7):1230-1240. 10.1016/S0149-2918(00)80025-9, 10463520.
15. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999, 52(6):1138-1145.
16. Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Mastey V, Haglund A, Zhang R, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003, 15(1):44-54. 10.1159/000066669, 12457078.
17. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 1998, 13(7):445-453. 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E, 9695032.
18. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2007, 257(6):330-336. 10.1007/s00406-007-0727-1, 17404699.
19. Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: A UK evaluation using discrete-event simulation. Pharmacoeconomics 2010, 28(5):411-427. 10.2165/11531870-000000000-00000, 20402542.
20. Getsios D, Blume S, Ishak KJ, Maclaine GD. Supplemental Digital Content: Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease. 2010, , http://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/PCZ/A/PCZ_28_5_2010_01_24_GETSIOS_1153187_SDC1.pdf
21. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten. Version 1.0 vom 12.10.2009., http://www.iqwig.de/download/Methodik_fuer_die_Bewertung_von_Verhaeltnissen_zwischen_Kosten_und_Nutzen.pdf
22. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005, 23(4):323-332. 10.2165/00019053-200523040-00003, 15853433.
23. Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations?. Value Health 2010, 13(8):1056-1060. 10.1111/j.1524-4733.2010.00775.x, 20825626.
24. Hollingworth W, Spackman DE. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation. Acad Radiol 2007, 14(4):406-410. 10.1016/j.acra.2007.01.007, 17368208.
25. Bosanquet N, Yeates A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2006, 24(6):623-625. author reply 625-626, 10.2165/00019053-200624060-00008, 16761908.
26. Oremus M. Systematic review of economic evaluations of Alzheimer's disease medications. Expert Rev Pharmacoecon Outcomes Res 2008, 8(3):273-289. 10.1586/14737167.8.3.273, 20528379.
27. Tun SM, Murman DL, Long HL, Colenda CC, von Eye A. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007, 15(4):314-327. 10.1097/01.JGP.0000239263.52621.97, 17384314.
28. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57(3):481-488.
29. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57(3):489-495.
30. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57(4):613-620.
31. Gesundheitsberichterstattung des Bundes. , http://www.gbe-bund.de/
32. Consortium to Establish a Registry for Alzheimer's Disease (CERAD). , http://cerad.mc.duke.edu/Default.htm
33. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998, 50(1):136-145.
34. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998, 158(9):1021-1031. 10.1001/archinte.158.9.1021, 9588436.
35. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007, 69(5):459-469. 10.1212/01.wnl.0000266627.96040.5a, 17664405.
36. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367(9516):1057-1065. 10.1016/S0140-6736(06)68350-5, 16581404.
37. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001, 58(3):427-433. 10.1001/archneur.58.3.427, 11255446.
38. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006, 21(5-6):353-363. 10.1159/000091790, 16508298.
39. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994, 151(3):390-396.
40. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 2000, 19(11-12):1607-1616. 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1607::AID-SIM449>3.0.CO;2-O, 10844722.
41. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000, 19(11-12):1401-1409. 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1401::AID-SIM432>3.0.CO;2-X, 10844705.
42. McShane R, Areosa Sastre A, Minakaran N. Memantine for Dementia (Review) 2007, The Cochrane Library: JohnWiley & Sons.
43. Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord 2008, 25(3):226-231. 10.1159/000114450, 18230972.
44. Deutsches Statistisches Bundesamt. , http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Navigation/Navigationsknoten__Startseite.psml
45. Xie J, Brayne C, Matthews FE. Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ 2008, 336(7638):258-262. 10.1136/bmj.39433.616678.25, 2223023, 18187696.
46. Kassenärztliche Bundesvereinigung. , http://www.kbv.de/8144.html
47. Hallauer JF, Schons M, Smala A, Berger K. Untersuchung von Krankheitshosten bei patienten mit alzheimer-erkrankung in Deutschland. Gesundheitsökonomie und Qualitätsmanagement 2000, 5:73-79.
48. European Commission: Eurostat. , http://epp.eurostat.ec.europa.eu/portal/page?_pageid=2714,1,2714_61582070&_dad=portal&_schema=PORTAL
49. Rote Liste. , http://www.rote-liste.de/
50. Kulp W, Graf GVD, Schulenburg J-M. Pharmakoökonomische Aspekte der Behandlung von Demenz-Patienten. Pharmazie unserer Zeit 2002, 31(4):410-416.
51. Jonsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jonhagen ME, Hallikainen M, Wimo A. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006, 20(1):49-55. 10.1097/01.wad.0000201851.52707.c9, 16493236.
52. Schwarzkopf LMP, Kunz S, Holle R, Lauterberg J, Marx P, Mehlig H, Wunder S, Leidl R, Donath C, Graessel E. Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value Health 2011, 14(6):827-835. 10.1016/j.jval.2011.04.005, 21914502.
53. Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer's disease. Drugs Aging 2012, 29(1):31-43. 10.2165/11597380-000000000-00000, 22191721.
54. Reese J, Seeberg G, Henkel D, Hirzmann P, Rieke J, Baum E, Dannhoff F, Müller MJ, Jessen F, Geldsetzer MB, Dodel R. Cost and care of patients with Alzheimer's Disease: clinical predictors in German health care settings. J Alzheimers Dis 2011, 27(4):723-736.
55. Leicht HHS, Heider D, Bachmann C, Bickel H, van den Bussche H, Fuchs A, Luppa M, Maier W, Mösch E, Pentzek M, Rieder-Heller SG, Tebarth F, Werle J, Weyerer S, Wiese B, Zimmermann T, König HH. AgeCoDe study group: Net costs of dementia by disease stage. Acta Psychiatr Scand 2011, 124(5):384-395. 10.1111/j.1600-0447.2011.01741.x, 21838738.
56. Kiencke PRR, Grimm C, Daniel D. Cost of illness in Alzheimer's disease. Med Klin (Munich) 2010, 105(a5):327-333.